South Africa Brokers Deal To Cut Price Of TB Drug Bedaquiline As Nations Prepare For U.N. High-Level Meeting

Devex: South Africa strikes deal on new TB drug as WHO revisits guidance
“The World Health Organization could soon start promoting a new tuberculosis drug that is now more affordable after South Africa brokered a deal with a pharmaceutical company to slash the price by half. WHO had previously issued guidance limiting the use of the breakthrough drug bedaquiline, but told Devex it is looking to revise this in the wake of new evidence about its effectiveness in treating people with drug-resistant TB. The news comes as countries prepare to meet in New York for the first United Nations high-level meeting on TB in September, which advocates hope will translate into increased political commitment to eradicating the infectious disease…” (Edwards, 8/9).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.